Cipla has received regulatory approval in India from the Drug Controller General of India (DCGI) to sell its version of Truvada as a preventive that can be given to healthy people to reduce their risk of getting HIV. Truvada is priced at Rs 2,200 for a month. The Truvada has been in use in India for about eight years now, but only for the treatment of people with the HIV infection. The big difference now is that it is used to prevent infection in healthy people.
Cipla has emerged as one of the most respected pharmaceutical names in India as well as across more than 150 countries. Its portfolio includes 1500 plus products across therapeutic categories with one quality standard globally.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1668.75 |
| Dr. Reddys Lab | 1233.95 |
| Cipla | 1231.60 |
| Zydus Lifesciences | 938.70 |
| Lupin | 2328.25 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: